Protocol Ledger

NCT05456685 · Phase II · ACTIVE NOT RECRUITING

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Interventional Phase II clinical trial protocol NCT05456685 sponsored by AbbVie in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-28 Enrollment: 125 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05456685
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)125 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05456685
Protocol FieldVerified Registry Value
NCT IdentifierNCT05456685
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment125 participants (ACTUAL)
Registered Start Date2022-09-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI